Jaguar Health, Inc. Receives Nasdaq Delisting Notice After Failing to Meet Minimum Bid Price Requirement
San Francisco, CA – March 6, 2026 – Jaguar Health, Inc. (Nasdaq: JAGX), a pharmaceutical company headquartered in San Francisco, has announced via a Form 8-K filing that it received a formal written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March 5, 2026, regarding non-compliance with the minimum bid price requirement for continued listing.
Key Points of the Report
- Nasdaq Delisting Notice: Jaguar Health’s common stock has closed below the minimum \$1.00 per share bid price for the previous 30 consecutive business days. This triggered non-compliance with Nasdaq Listing Rule 5550(a)(2).
- No Compliance Period Eligibility: The company is not eligible for any compliance period under Nasdaq Listing Rule 5810(c)(3)(A). This is because Jaguar Health effected a reverse stock split within the past year, or has conducted one or more reverse stock splits in the prior two-year period with a cumulative ratio of 250 shares or more to one.
- Potential Delisting Timeline: Unless Jaguar Health requests an appeal before a Nasdaq Hearings Panel by March 12, 2026, its securities will be scheduled for delisting from Nasdaq.
- Company Response: Jaguar Health intends to timely request a hearing before the Panel, which will automatically stay any further suspension or delisting action by Nasdaq at least pending the outcome of the hearing process.
- Uncertainty Remains: There is no assurance that the Panel will grant the company’s request for continued listing, or that Jaguar Health will be able to regain compliance and maintain its Nasdaq listing in the future.
Important Information for Shareholders
- Potential Share Price Impact: The possibility of delisting from Nasdaq is a highly material event for shareholders. Delisting can significantly reduce the liquidity and visibility of Jaguar Health’s common stock, potentially leading to a sharp decline in share value and limited trading options.
- Reverse Stock Split History: The company’s use of multiple or large ratio reverse stock splits signals ongoing challenges in maintaining compliance with Nasdaq’s listing standards, which may be concerning for existing and prospective investors.
- Uncertain Path Forward: Even with an appeal, there is no guarantee Jaguar Health will maintain its Nasdaq listing. If the Panel does not grant continued listing, the company may be relegated to trading on the OTC markets, which generally offer less liquidity and lower investor interest.
- Forward-Looking Statements: The company has provided cautionary language regarding forward-looking statements. Actual results may differ materially from expectations due to risks described in Jaguar Health’s filings with the SEC, including its most recent Annual Report on Form 10-K and other public disclosures.
Additional Corporate Details
- Company Name: Jaguar Health, Inc.
- Trading Symbol: JAGX
- Exchange: The Nasdaq Stock Market
- Principal Executive Office: 200 Pine Street, Suite 400, San Francisco, CA 94104
- Telephone Number: (415) 371-8300
- CEO & President: Lisa A. Conte
- State of Incorporation: Delaware
- SEC File Number: 001-36714
What Should Investors Do?
- Closely monitor updates from Jaguar Health regarding the outcome of the Nasdaq appeal process.
- Review the company’s recent SEC filings, especially risk factors and management discussions, for additional context on challenges facing the business.
- Consider the potential impact of a Nasdaq delisting on their investment strategy, including possible liquidity constraints and increased volatility.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consider consulting with a qualified financial advisor before making investment decisions. The forward-looking statements included herein are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
View Jaguar Health, Inc. Historical chart here
